Table of Content

Table of Contents

            Abbreviations

1          Executive Summary

2          Introduction & Overview

3          Stakeholder Analysis

3.1       Overview

3.2       Vectorized Antibody Technology Companies

3.3       Pharma/Biotech Companies Partnered with Vectorized Antibody Technology Companies

4          Profiles of Stakeholders in Vectorized Antibody Technologies

4.1       Viral Vector DNA Companies       

4.1.1    4D Molecular Therapeutics (4DMT)

4.1.2    Adverum Biotechnologies

4.1.3    Homology Medicines

4.1.4    MeiraGTx

4.1.5    REGENXBIO

4.1.6    University of Pennsylvania (U’Penn), Wilson Gene Therapy Program (GTP)

4.1.7    VectorY

4.1.8    Voyager Therapeutics

4.1.9    Vybion

4.2       Plasmid DNA Companies   

4.2.1    Eyevensys

4.2.2    Generation Bio

4.2.3    Inovio Pharmaceuticals

4.2.4    SmartPharm Therapeutics & Sorrento Therapeutics

4.3       mRNA Companies  

4.3.1    BioNTech

4.3.2    CureVac

4.3.3    Ethris

4.3.4    Kernal Biologics

4.3.5    Moderna Therapeutics

4.4       Pharma / Biotech Partner Companies     

4.4.1    AbbVie

4.4.2    AstraZeneca

4.4.3    Genmab

4.4.4    GlaxoSmithKline

4.4.5    Merck

4.4.6    Neurimmune

4.4.7    Regeneron Pharmaceuticals

4.4.8    Vir Biotechnology

5          Analysis of Vectorized Antibody Technologies

5.1       Viral Vector DNA Technologies for In Vivo Expression of Antibodies

5.2       Plasmid DNA Technologies for In Vivo Expression of Antibodies

5.3       mRNA Technologies for In Vivo Expression of Antibodies

6          Profiles of Vectorized Antibody Technologies

6.1       Viral Vector DNA Technologies for In Vivo Expression of Antibodies           

6.1.1    Therapeutic Vector Evolution by 4D Molecular Therapeutics (4DMT)

6.1.2    Engineered AAV Technology by Adverum Biotechnologies

6.1.3    GTx-mAbs Platform by Homology Medicines

6.1.4    AAV Technology for Antibody Expression in Vivo by MeiraGTx

6.1.5    NAV Technology Platform by REGENXBIO

6.1.6    TRACER System for Discovering Novel Gene Therapy Capsids by Voyager Therapeutics

6.2       Plasmid DNA Technologies for In Vivo Expression of Antibodies       

6.2.1    Ciliary Electrotransfection & DNA Plasmids by Evensys

6.2.2    Non-viral Antibody Gene Therapy (AGT) Platform by Generation Bio

6.2.3    Synthetic DNA-based Monoclonal Antibody (dMAb) Tecnology Platform by Inovio Pharmaceuticals

6.2.4    Gene-Encoded Antibody (Gene MAb) Technology by SmartPharm Therapeutics

6.3       mRNA Technologies for In Vivo Expression of Antibodies      

6.3.1    RiboMAb Technology by BioNTech

6.3.2    RNAoptimizer Technology Platform by Curevac

6.3.3    SNIM RNA Technology by Ethris

6.3.4    mRNA Antibodies & Lipid Nanoparticles for Delivery by Moderna Therapeutics

7          Analysis of Pipeline and Product Candidates for In Vivo Expression of Antibodies

7.1       AAV DNA for In Vivo Expression of Antibodies: Analysis of Pipeline and Selected Product Candidates

7.2       Plasmid DNA for In Vivo Expression of Antibodies: Analysis of Pipeline and Selected Product Candidates

7.3       mRNA for In Vivo Expression of Antibodies: Analysis of Pipeline and Selected Product Candidates

8          Profiles of Vectorized Antibody Product Candidates

8.1       Viral Vector DNA Product Candidates for In Vivo Expression of Antibodies    

8.1.1    4D-150

8.1.2    ADVM-022; AAV.7m8-aflibercept

8.1.3    Anti-Tau Vectorized Antibodies

8.1.4    INT41

8.1.5    RGX-314

8.1.6    Vectorized Anti-Kallikrein Antibody

8.2       Plasmid DNA Product Candidates for In Vivo Expression of Antibodies           

8.2.1    Antibody Gene Therapy (AGT) – Generation Bio

8.2.2    Anti-VEGF ceDNA-ctLNP

8.2.3    Further dMAb Experience

8.2.4    EYS606

8.2.5    INO-A002; dMAb-ZK190; Zika dMAb

8.2.6    STI-8472: COVI-GeneMAB

8.3       mRNA Product Candidates for In Vivo Expression of Antibodies      

8.3.1    CureVac mRNA Antibodies

8.3.2    mRNA-1944

8.3.3    ETH46; NI007

9          Business, Financing & Partnering

9.1       Business

9.2       Financing

9.3       Partnering

10        References



List of Tables


Figures & Tables
Table 1    Corporate Stakeholders in Vectorized Antibody R&D
Table 2    Range of Product Categories Leveraged by Companies from Use of In Vivo Expression Technologies
Table 3    Profiles of Stakeholders with Vectorized Antibody Technologies
Table 4    Pharma/Biotech Partnerships with Vectorized Antibody Technology Companies
Table 5    REGENXBIO’s Pipeline of Vectorized Antibodies
Table 6    Generation Bio’s Pipeline of Antibody Gene Therapies
Table 7    Advantages of Viral Vector DNA for In vivo Expression of Antibodies
Tables 8    Profiles of Viral Vectors for In Vivo Expression of Antibodies
Table 9    Advantages of Plasmid DNA for In Vivo Expression of Antibodies
Table 10    Profiles of Plasmid DNA for In Vivo Expression of Antibodies
Table 11    Advantages of mRNA for In Vivo Expression of Antibodies
Table 12    Profiles of mRNA for In Vivo Expression of Antibodies
Table 13    Pipeline of Vectorized Antibodies Encoded by AAV DNA
Table 14    Overview of Profiled AAV DNA Product Candidates for In Vivo Expression of Antibodies
Table 15    Pipeline of Vectorized Antibodies Encoded by Plasmid DNA
Table 16    Overview of Profiled Plasmid DNA Product Candidates for In Vivo Expression of Antibodies
Table 17    Pipeline of Vectorized Antibodies Encoded by mRNA
Table 18    Overview of Profiled mRNA Product Candidates for In Vivo Expression of Antibodies
Table 19    Funding of Vectorized Antibody Programs
Table 20    Financial Terms of Partnering Deals Based on Antibody Vector Technology
Table 21    Technology Contributions in Partnering Deals

 
ADDENDUM
Add 1    Competitor Analysis of AAV DNA Vectorized Antibodies
Add 2    Competitor Analysis of plasmid DNA Vectorized Antibodies
Add 3    Competitor Analysis of mRNA Vectorized Antibodies